Please upgrade your browser.
This means many patients who are candidates for less radical surgical procedures, such as a partial nephrectomy where only part of the kidney is removed, may not be getting them, the California researchers said.
Oxford BioMedica (LSE: OXB), a leading gene therapy company, announced today that it has successfully completed patient enrolment in the Phase III TRIST study of TroVax in renal cancer.
In the podcast Ms. Clift candidly recounts what was going on in her life in the two weeks before the death of her husband, Tom, from kidney cancer. She also suggests ways of coping with the impending death of a loved one that might be helpful to others.
Hannie van der Kaay, has already had to come up with more than $7,500 to receive 28 days of a medication called Sutent a pill to treat his kidney cancer. The province won't assist in covering the cost.
In the popular mind, drug prices are excessive. Why should you have to pay a few bucks for a pill that costs pennies to make?
The Kidney Cancer Association and the 60 Plus Association, groups representing patients and seniors, respectively, joined the industry in claiming that federal patent law preempted D.C.'s price control regime.
The toxin decreases the blood supply to the tumor, causing its growth to slow. But the toxin does not affect the blood supply to normal cells. Researchers have still to discover why.
A man with kidney cancer says he has been refused a drug that could save his life and is still waiting for treatment 18 months after being diagnosed.
Newsweek's Eleanor Clift has filled the three years since her husband's death from kidney cancer at age 64 by telling his story in a touchingly personal memoir.
Two leading cancer centers show the same remarkably successful result for kidney cryoablation.
An on-going phase 2, stage A, trial in patients with renal cell carcinoma. At present, one patient continues to receive treatment in this phase 2 trial. The Company expects that final data from this trial will be available in the second or third quarter of 2008.
|Powered by NeonCRM|